Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001609251-18-000004
Filing Date
2018-02-15
Accepted
2018-02-14 21:27:36
Documents
1

Document Format Files

Seq Description Document Type Size
1 KRENSAVAGE 13G AVIR 12.31.2017 AMEND 2 AVIR_13G_12.31.2017_A2.txt SC 13G 16100
  Complete submission text file 0001609251-18-000004.txt   17931
Mailing Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009
Business Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009 301-770-3099
Aviragen Therapeutics, Inc. (Subject) CIK: 0000072444 (see all company filings)

EIN.: 591212264 | State of Incorp.: DE | Fiscal Year End: 0630
Type: SC 13G | Act: 34 | File No.: 005-31596 | Film No.: 18615937
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 610 FIFTH AVENUE SUITE 301 NEW YORK NY 10020
Business Address 610 FIFTH AVENUE SUITE 301 NEW YORK NY 10020 212-888-1582
Krensavage Asset Management, LLC (Filed by) CIK: 0001609251 (see all company filings)

EIN.: 262520930 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G